Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lonafarnib improves cardiovascular function and survival in a mouse model of Hutchinson-Gilford progeria syndrome

9 Mar 2023

Abstract excerpt

Clinical trials have demonstrated that lonafarnib, a farnesyltransferase inhibitor, extends the lifespan in patients afflicted by Hutchinson-Gilford progeria syndrome, a devastating condition that accelerates many characteristics of aging and results in premature death due to cardiovascular sequelae. The US Food and Drug Administration approved Zokinvy (lonafarnib) in November 2020 for treating these patients,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Nuclear Structure and Function
Share to PARP inhibition in cancer therapy
Share to RNA Research and Splicing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36930696
DOI: 10.7554/elife.82728

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lonafarnib improves cardiovascular function and survival in a mouse model of Hutchinson-Gilford progeria syndromePMID 36930696Read ↗

Lonafarnib improves cardiovascular function and survival in a mouse model of Hutchinson-Gilford Progeria SyndromeSemantic proximity Read ↗

Paradoxical Aortic Stiffening and Subsequent Cardiac Dysfunction in Hutchinson-Gilford Progeria SyndromeSemantic proximity Read ↗

Paradoxical aortic stiffening and subsequent cardiac dysfunction in Hutchinson-Gilford progeria syndrome.Semantic proximity Read ↗

Molecular and Cellular Mechanisms Driving Cardiovascular Disease in Hutchinson-Gilford Progeria Syndrome: Lessons Learned from Animal Models.Semantic proximity Read ↗

Progress and trends in the development of therapies for Hutchinson–Gilford progeria syndromeSemantic proximity Read ↗

Improved Arterial Stiffness and Bone Mineral Density in Hutchinson–Gilford Progeria Treated with Bone Marrow-Derived Mesenchymal Stem Cells: A Case Study and Literature ReviewSemantic proximity Read ↗

Metabolic Dysfunction in Hutchinson–Gilford Progeria SyndromeSemantic proximity Read ↗

Vascular organoid model of Hutchinson-Gilford progeria syndrome uncovers repression of the SRF pathway in premature aging.Semantic proximity Read ↗

Endothelial YAP/TAZ activation promotes atherosclerosis in a mouse model of Hutchinson-Gilford progeria syndromeSemantic proximity Read ↗

Intervention for Critical Aortic Stenosis in Hutchinson-Gilford Progeria SyndromeSemantic proximity Read ↗

Evaluation of musculoskeletal phenotype of the G608G progeria mouse model with lonafarnib, pravastatin, and zoledronic acid as treatment groups.Semantic proximity Read ↗

Progerinin, an Inhibitor of Progerin, Alleviates Cardiac Abnormalities in a Model Mouse of Hutchinson-Gilford Progeria Syndrome.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.